In conclusion, by inhibiting the JAK/STAT1 signaling pathway to reduce the expression of CXCL10, it can reduce inflammatory cell infiltration, reduce or block the inflammatory response, and is expected to become a potential treatment for LN. Here, CXCL10 is linked to lobular neoplasia.